

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vrignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/066,285	02/01/2002	Greg Fahy	074066-0115	3778
20995	7590 07/02/2003			
	IARTENS OLSON &	EXAMINER		
2040 MAIN S FOURTEEN	TH FLOOR	SAUCIER, SANDRA E		
IRVINE, CA	92614		ART UNIT	PAPER NUMBER
			1651 DATE MAILED: 07/02/2003	þ

Please find below and/or attached an Office communication concerning this application or proceeding.



Office Action Summary

Application No. 10/066,285

Applicant(s)

Examiner

Fahy et al.

Sandra Saucier

1651



•	The MAILING DATE of this communication appears of	n the cover sheet with the correspondence address		
	for Reply			
THE	ORTENED STATUTORY PERIOD FOR REPLY IS SET TAILING DATE OF THIS COMMUNICATION.	O EXPIRE MONTH(S) FROM o event, however, may a reply be timely filed after SIX (6) MONTHS from the		
mailing	date of this communication.			
- If NO p - Failure - Any re	period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply an to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	d will expire SIX (6) MONTHS from the mailing date of this communication. application to become ABANDONED (35 U.S.C. § 133).		
Status				
1) 🗌	Responsive to communication(s) filed on			
2a) 🗌	This action is FINAL . 2b) ✓ This action	on is non-final.		
3) 🗆	Since this application is in condition for allowance exclosed in accordance with the practice under Ex par	xcept for formal matters, prosecution as to the merits is te Quayle, 1935 C.D. 11; 453 O.G. 213.		
Disposit	tion of Claims			
4) 💢	Claim(s) <u>1-35</u>	is/are pending in the application.		
4	a) Of the above, claim(s)	is/are withdrawn from consideration.		
5) 🗆	Claim(s)	is/are allowed.		
6) 🗆	Claim(s)	is/are rejected.		
7) 🗆	Claim(s)	is/are objected to.		
8) 💢	Claims <u>1-35</u>	are subject to restriction and/or election requirement.		
Applica	ition Papers			
9) 🗆	The specification is objected to by the Examiner.			
10)□	The drawing(s) filed on is/are	a) \square accepted or b) \square objected to by the Examiner.		
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).			
11)□	11) \square The proposed drawing correction filed on is: a) \square approved b) \square disapproved by the Examine			
	If approved, corrected drawings are required in reply to	this Office action.		
12)	The oath or declaration is objected to by the Examin	ner.		
_	under 35 U.S.C. §§ 119 and 120			
13)	Acknowledgement is made of a claim for foreign pri	ority under 35 U.S.C. § 119(a)-(d) or (f).		
a) [☐ All b)☐ Some* c)☐ None of:			
	1. \square Certified copies of the priority documents have	e been received.		
	2. \square Certified copies of the priority documents have	been received in Application No		
	application from the International Burea			
_	ee the attached detailed Office action for a list of the			
_	Acknowledgement is made of a claim for domestic The translation of the foreign language provisional			
	Acknowledgement is made of a claim for domestic			
Attachm	-	priority ariable de district 33 125 aria/or 1211		
	otice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).		
2) No	otice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)		
3) 🗌 Inf	formation Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:		

Application/Control Number: 10/066285 Page 2

Art Unit: 1651

DETAILED ACTION

Claims 1-35 are pending and subject to restriction.

Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 7, 8, 19, 20, drawn to a solution comprising polyglycerol, lactose, chondroitin sulfate, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.
- II. Claims 9-11, drawn to a solution comprising polyglycerol lactose, chlorpromazine, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.
- III. Claim 12, drawn to a solution comprising polyglycerol lactose, calcium, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.
- IV. Claim 13, drawn to a solution comprising polyglycerol lactose, citrate, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.
- V. Claim 14, drawn to a solution comprising polyglycerol lactose, glutathione, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.
- VI. Claim 15, drawn to a solution comprising polyglycerol lactose, phosphate buffer, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.
- VII. Claim 16, drawn to a solution comprising polyglycerol lactose, glucose, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.
- VIII. Claim 17, drawn to a solution comprising polyglycerol lactose, adenine, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.
- IX. Claim 18, drawn to a solution comprising polyglycerol lactose, magnesium, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.

Application/Control Number: 10/066285

Art Unit: 1651

- X. Claims 21-32, drawn to a method comprising contacting cells, tissue, organ with a polyglycerol solution, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.
- XI. Claims 33-35, drawn to a method comprising contacting cells, tissue, organ with a lactose solution, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.

The inventions are distinct, each from the other because of the following reasons:

Groups I-IX are distinct compositions because they have distinct components and are therefore restrictable.

For example, a composition, A, may not be restricted from compositions A+B, or from A+B+C, or from A+B+C+D as these form a tree of further limitations. However, compositions A+B and A+C and A+D, etc. are distinct compositions and may be properly restricted.

Claims 1-6 are generic and will be examined with elected Group I-IX.

The method of use of Group X does not require the presence of lactose as is required by the compositions of Groups I-IX. Therefore, it is not a method of use of any of the composition Groups I-IX.

The method of use of Group XI does not require the presence of polyglycerol as is required by the compositions of Groups I-IX. Therefore, it is not a method of use of any of the composition Groups I-IX.

The processes of Groups X and XI are distinct from one another because they recite the use of distinct compositions. The process of Group X does not require lactose which is the only component required by the process of Group IX.

The several inventions listed above are independent and distinct from one another as they have acquired a separate status in the art and require independent searches, particularly with regard to the literature searches. Clearly, a reference which would anticipate one of the above groups would not necessarily anticipate or even make obvious any of the others.

Art Unit: 1651

An undue burden would ensue from the examination of multiple methods which have distinct steps and end points. Burden lies not only in the search of US Patents, but in the search for literature and foreign patents and examination of the claim language and specification for compliance with the statutes concerning new matter, distinctness and scope of enablement.

Because these inventions are distinct for the reasons given above restriction for examination purposes as indicated is proper.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1651. The supervisor for 1651 is M. Wityshyn, (703) 308-4743. The normal work schedule for Examiner Saucier is 8:30AM to 5:00 PM Monday and Tuesday and 8:30 to noon on Wednesday.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sandra Saucier whose telephone number is (703) 308–1084. Status inquiries must be directed to the Customer Service Desk at (703) 308–0197 or (703)–308–0198. The number of the Fax Center for the faxing of papers is (703) 308–2742 or (703) 305–3592.

Sandra Saucier Primary Examiner Art Unit 1651

July 1, 2003